

# Canadian spontaneous coronary artery dissection cohort study: in-hospital and 30-day outcomes

Jacqueline Saw<sup>1</sup>\*, Andrew Starovoytov<sup>1</sup>, Karin Humphries<sup>2</sup>, Tej Sheth<sup>3</sup>, Derek So<sup>4</sup>, Kunal Minhas<sup>5</sup>, Neil Brass<sup>6</sup>, Andrea Lavoie<sup>7</sup>, Helen Bishop<sup>8</sup>, Shahar Lavi<sup>9</sup>, Colin Pearce<sup>10</sup>, Suzanne Renner<sup>11</sup>, Mina Madan<sup>12</sup>, Robert C. Welsh<sup>13</sup>, Sohrab Lutchmedial<sup>14</sup>, Ram Vijayaraghavan<sup>15</sup>, Eve Aymong<sup>16</sup>, Bryan Har<sup>17</sup>, Reda Ibrahim<sup>18</sup>, Heather L. Gornik<sup>19</sup>, Santhi Ganesh<sup>20</sup>, Christopher Buller<sup>21</sup>, Alexis Matteau<sup>22</sup>, Giuseppe Martucci<sup>23</sup>, Dennis Ko<sup>12</sup>, and Giovanni Battista John Mancini<sup>1</sup>

<sup>1</sup>Division of Cardiology, Vancouver General Hospital, 2775 Laurel St, 9th Floor, Vancouver, British Columbia V5Z 1M9, Canada; <sup>2</sup>BC Centre for Improved Cardiovascular Health, Vancouver, British Columbia, Canada; <sup>3</sup>Hamilton General Hospital, Hamilton, Ontario, Canada; <sup>4</sup>University of Ottawa Heart Institute, Ottawa, Ontario, Canada; <sup>5</sup>Saint Boniface General Hospital, Winnipeg, Manitoba, Canada; <sup>6</sup>Royal Alexandra Hospital, Edmonton, Alberta, Canada; <sup>7</sup>University of Saskatchewan & Prairie Vascular, Regina, Saskatchewan, Canada; <sup>8</sup>Queen Elizabeth Health Sciences Centre, Halifax, Nova Scotia, Canada; <sup>9</sup>London Health Sciences Centre, London, Ontario, Canada; <sup>10</sup>Royal University Hospital, Saskatoon, Saskatchewan, Canada; <sup>11</sup>St. Mary's General Hospital, Kitchener, Ontario, Canada; <sup>12</sup>Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; <sup>13</sup>University of Alberta, Edmonton, Alberta, Canada; <sup>14</sup>St. John Regional Hospital, St. John, New Brunswick, Canada; <sup>15</sup>Scarborough Cardiology Research, Scaborough, Ontario, Canada; <sup>16</sup>Cleveland Clinic Foundation, Cleveland, OH, USA; <sup>20</sup>University of Michigan, Ann Arbor, MI, USA; <sup>21</sup>St. Michael's Hospital, Toronto, Ontario, Canada; <sup>22</sup>Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada; and <sup>23</sup>McGill University Health Centre, Montreal, Quebec, Canada;

Received 22 August 2018; revised 6 November 2018; editorial decision 7 January 2019; accepted 8 January 2019

| Aims                   | Spontaneous coronary artery dissection (SCAD) was underdiagnosed and poorly understood for decades. It is in-<br>creasingly recognized as an important cause of myocardial infarction (MI) in women. We aimed to assess the nat-<br>ural history of SCAD, which has not been adequately explored.   |
|------------------------|---|
| Methods<br>and results | We performed a multicentre, prospective, observational study of patients with non-atherosclerotic SCAD presenting acutely from 22 centres in North America. Institutional ethics approval and patient consents were obtained. We recorded baseline demographics, in-hospital characteristics, precipitating/predisposing conditions, angiographic features (assessed by core laboratory), in-hospital major adverse events (MAE), and 30-day major adverse cardiovascular events (MACE). We prospectively enrolled 750 SCAD patients from June 2014 to June 2018. Mean age was $51.8 \pm 10.2$ years, 88.5% were women (55.0% postmenopausal), 87.7% were Caucasian, and 33.9% had no cardiac risk factors. Emotional stress was reported in 50.3%, and physical stress in 28.9% (9.8% lifting >50 pounds). Predisposing conditions included fibromuscular dysplasia 31.1% (45.2% had no/incomplete screening), systemic inflammatory diseases 4.7%, peripartum 4.5%, and connective tissue disorders 3.6%. Most were treated conservatively (84.3%), but 14.1% underwent percutaneous coronary intervention and 0.7% coronary artery bypass surgery. In-hospital composite MAE was 8.8%; peripartum SCAD patients had higher in-hospital MAE (20.6% vs. 8.2%, $P = 0.023$ ). Overall 30-day MACE was 8.8%. Peripartum SCAD and connective tissue disease were independent predictors of 30-day MACE. |
| Conclusion             | Spontaneous coronary artery dissection predominantly affects women and presents with MI. Despite majority of patients being treated conservatively, survival was good. However, significant cardiovascular complications occurred within 30 days. Long-term follow-up and further investigations on management are warranted.   |
| Keywords               | Spontaneous coronary artery dissection (SCAD) • Myocardial infarction (MI) • Women • Fibromuscular dysplasia (FMD) • Peripartum • Percutaneous coronary intervention (PCI)  |

\* Corresponding author. Tel: +1 604 875 5547, Fax: +1 604 875 5563, Email: jsaw@mail.ubc.ca

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

## Introduction

Spontaneous coronary artery dissection (SCAD) is an underdiagnosed and poorly understood condition that frequently affects young women without cardiovascular (CV) risk factors and can cause myocardial infarction (MI), cardiac arrest, or death.<sup>1</sup> Spontaneous coronary artery dissection is defined as a spontaneous, nontraumatic, non-iatrogenic, and non-atherosclerotic separation of the coronary arterial wall by intramural haemorrhage, which can be elicited by intimal tear or spontaneous haemorrhage.<sup>1</sup> This creates a false lumen with intramural haematoma (IMH) that compresses the true lumen causing myocardial ischaemia or infarction. Spontaneous coronary artery dissection typically occurs from an underlying predisposing arteriopathy that weakens the wall, with or without precipitating stressors.<sup>1, 2</sup>

Spontaneous coronary artery dissection was previously reported as rare, however, it had been underdiagnosed and the true prevalence is unknown. In a large 2009–14 National Inpatient Sample analysis, ~1% of ~750 000 women with MI who underwent coronary angiography were reported to have SCAD.<sup>3</sup> However, in contemporary studies with improved SCAD diagnosis, SCAD was reported to cause 24–35% of MI in women age <60 years.<sup>4</sup> Among men and women presenting with acute coronary syndrome (ACS) undergoing coronary angiography, SCAD was reported in 1.0–4.0%.<sup>2,3</sup> Since angiography does not image arterial walls, intracoronary imaging [optical coherence tomography (OCT) or intravascular ultrasound (IVUS)] may be necessary to confirm SCAD in ambiguous cases.<sup>5</sup> New angiographic SCAD classification<sup>6</sup> has aided SCAD diagnosis on angiography, which remains the current gold-standard for diagnosis.

Despite recent improvements in diagnosis and recognition of the importance of SCAD, it remains poorly studied and understood. Spontaneous coronary artery dissection publications are mostly limited to case reports and non-prospective series, with absence of randomized trial data. Both the American Heart Association and European Society of Cardiology, SCAD working groups recently published scientific statements summarizing the evidence to date and recommendations for management and screening.<sup>2,7</sup> However, there are diverse aetiologies, stressors, and management strategies, with as yet unclear estimates of recurrence and prognosis. Therefore, we designed the Canadian SCAD cohort study, a large, observational, prospective, cohort study, to describe the natural history of SCAD and to provide the justification and foundation for future randomized clinical trials. Here, we report the in-hospital and 30-day outcomes.

# Methods

This is a multicentre, prospective, observational study of consecutive patients with non-atherosclerotic SCAD from 20 centres across Canada and two centres in the United States (Supplementary material online, *Appendix S1*). The study was registered at ClinicalTrials.gov (NCT02188069) and approved by the local research ethics boards of each participating centre. All patients provided written informed consent for participation. We included patients with new SCAD presentation with ACS, and documented SCAD on coronary angiogram confirmed by core laboratory. We excluded patients with atherosclerotic disease in other coronary arterial segments with diameter stenosis ≥50%. The

study was managed by the University of British Columbia Cardiology Research group.

# Angiographic spontaneous coronary artery dissection diagnosis

All coronary angiograms were reviewed by the independent Cardiovascular Imaging Research core laboratory and classified according to the Saw angiographic SCAD classification.<sup>6</sup> In brief. Type 1 SCAD (evident wall stain) depicts classic contrast dye staining of arterial wall with multiple radiolucent lumen, with or without dye hang-up or slow contrast clearing from the lumen. Type 2 SCAD (diffuse stenosis) depicts diffuse (>20 mm) and smooth narrowing that can vary in severity; Type 2A describes presence of normal arterial segments proximal and distal to SCAD; Type 2B describes dissection that extends to distal tip of the artery.<sup>5</sup> Type 3 SCAD (mimics atherosclerosis) depicts focal or tubular stenosis that appears similar to atherosclerosis, and typically requires OCT/IVUS to prove presence of IMH and/or intimal dissection. Coronary segments were defined by the Bypass Angioplasty Revascularization Investigation classification.<sup>8</sup> Other angiographic characteristics, left ventricular ejection fraction (LVEF), and wall motion abnormality were recorded.

#### **Baseline characteristics**

Baseline demographics, past medical history, pregnancy history, hormonal therapy, preceding emotional and physical stressors, CV risk factors, and family history were recorded from patient reviews, hospital records, and patient-completed questionnaires. All patients completed detailed questionnaires on potential predisposing and precipitating stressors, gynaecologic history, clinical symptoms, and family history. Emotional stress was defined as major stress at hospital admission, and categorized as  $\geq$ 3 severity on a 4-point scale (mild, moderate, high, or severe). The Perceived Stress Scale was also administered. Physical stress was defined as new or unusually intense physical activity within a week of hospitalization. Intense isometric activity was defined as lifting >50 pounds. Active and prior hormonal therapy and other potential precipitating stressors (e.g. intense retching, vomiting, straining with bowel movement, use of recreational drugs, active pregnancy, breastfeeding, labour and delivery) were recorded.

#### Hospital clinical characteristics

Hospital presentation, electrocardiogram (ECG), laboratory results, need for revascularization [percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG)], ventricular arrhythmia (sustained ventricular tachycardia or fibrillation), LVEF, cardiogenic shock, need for haemodynamic support, urgent repeat coronary angiography, and urgent repeat revascularization were recorded.

#### **Predisposing conditions**

Pregnancy history (gravidity and parity), current pregnancy or peripartum (3rd trimester or within 12 months of delivery)<sup>9</sup> state, presence of fibromuscular dysplasia (FMD), inherited connective tissue disorders (CTDs), systemic inflammatory conditions, and coronary artery spasm history were sought. Multiparity was defined as having given birth  $\geq$ 4 times and grand multiparity  $\geq$ 5 times with gestational age  $\geq$ 24 weeks; grand multigravida defined as pregnancy  $\geq$ 5 times.<sup>10</sup> Fibromuscular dysplasia screen was recommended for the renal, iliac, and cerebrovascular arteries with catheter-based or CT angiography at the discretion of site physicians.<sup>10,11</sup> Fibromuscular dysplasia diagnosis was defined according to the American Heart Association criteria of multifocal disease (string-of-bead appearance)<sup>12</sup> in  $\geq$ 1 extracoronary vasculature.

# Management of spontaneous coronary artery dissection


Treatment of SCAD was at the discretion of treating physicians. Conservative management was typically recommended if there was no ongoing ischaemia, chest pain, haemodynamic instability, ventricular arrhythmias, or left main (LM) dissection. Percutaneous coronary intervention was usually pursued for ongoing ischaemia, and CABG was reserved for patients with LM or extensive proximal multi-vessel SCAD.<sup>13</sup> Percutaneous coronary intervention outcomes were defined as (i) successful if angioplasty/stenting of the dissection accomplished final thrombolysis in myocardial infarction (TIMI) 3 flow with no residual dissection or stenosis  $\leq$ 50% of lumen diameter, and with final TIMI 3 or improved flow; and (iii) unsuccessful if angioplasty/stenting concluded with residual dissection or stenosis >50% of lumen diameter, or worsened TIMI flow compared to baseline, or extension of dissection requiring bail-out CABG.


#### **Clinical follow-up and outcomes**

Patients were followed routinely during their hospital stay, and after discharge by telephone/office contact at 1, 6, 12 months, and annually thereafter for 3 years. Patients were consented into the study preferably during the acute hospitalization, but may be enrolled within 3 months of the SCAD event if there were logistical challenges (e.g. patients transferred back to referral hospitals, angiograms done at non-enrolling sites). The Seattle Angina Questionnaire was administered at baseline 6, 12, 24, and 36 months. Medications administered on discharge and at each follow-up were recorded. In-hospital major adverse events (MAE) included the composite of all-cause mortality, stroke/transient ischaemic attack (TIA), re-infarction,<sup>14</sup> cardiogenic shock (requiring medical or mechanical haemodynamic support), congestive heart failure (CHF), cardiac arrest (severe ventricular arrhythmia requiring defibrillation or antiarrhythmic agents), repeat revascularization (or unplanned revascularization), and cardiac transplantation. High-risk presentation was defined as in-hospital death, cardiac arrest, cardiogenic shock, ejection fraction <35%, or LM dissection. Thirty-day major adverse cardiovascular events (MACE) included the composite of all-cause mortality, stroke/TIA, recurrent MI (including recurrent SCAD), CHF, and revascularization. Recurrent SCAD was defined as de novo recurrent spontaneous dissection with new MI symptoms and enzyme elevation, not involving extension of dissection of the original SCAD lesion.<sup>15</sup>

#### **Statistical analysis**

Patient characteristics were summarized with mean  $\pm$  standard deviation or median and interguartile range for continuous variables, and with counts and proportions for categorical variables. Event rates and 95% confidence intervals (CIs) are reported for each of in-hospital MAE, postdischarge 30-day MACE, and total 30-day MACE. Univariate and multivariable logistical regression analyses were performed to identify clinical predictors for each outcome. Based on clinical input, 18 predictors were evaluated using univariate models and considered for inclusion in multivariable models. Predictors tested included demographic (age), CV risk factors (hypertension, diabetes, dyslipidaemia, smoking, and CTDs), patient histories (depression, anxiety, prior cerebrovascular accident (CVA), number of pregnancies, post-partum, and use of fertility treatment), predisposing arteriopathies (FMD), and precipitating stressors (emotional, physical, isometric, and hormonal stress). Connective tissue disorder was forced into the multivariable model of in-hospital MAE as it was deemed to be clinically important. Other variables were selected using a forward selection method with a significance level of P-value <0.20. Odds ratios (ORs) with corresponding 95% Cls were reported.





The multivariable models for both in-hospital MAE and 30-day MACE are based on the female population only, which comprised 88.5% of the overall SCAD cohort. A two-sided *P*-value <0.05 was considered to indicate statistical significance. Statistical analyses were performed with SAS version 9.4 (Cary, NC, USA).

### Results

We prospectively enrolled 750 patients from June 2014 to June 2018 from 22 centres presenting with acute SCAD. The study enrolment flowchart is depicted in *Figure 1*, with complete follow-up at 1 month. Baseline characteristics are summarized in *Table 1*. Mean age was  $51.8 \pm 10.2$  years (range 24–89 years) (*Figure 2*), and majority were women (88.5%) and Caucasian (87.7%). At baseline, 33.9% had no CV risk factors, 32.5% had migraines, 19.5% depression, and 19.7% anxiety.

Among women with SCAD, 55.0% were post-menopausal (Supplementary material online, *Table SA*). Only 12.7% had no prior pregnancies; 10.1% had  $\geq$ 5 prior pregnancies, 9.6% had  $\geq$ 4 prior births, and 2.6% had  $\geq$ 5 births. Thirty-four (4.7%) were peripartum (1 in 3rd trimester pregnancy). Nineteen (2.9%) were still breastfeeding during SCAD presentation.

For hospital presentation (*Table 2*), 29.7% presented with ST-elevation MI, 69.9% non-ST-elevation MI. Ventricular tachycardia/ fibrillation occurred in 8.1% (3.9% required cardioversion or

Table I Baseline demographics

| Age (years) $51.8 \pm 10.2$ Sex (female) $664$ (88.5)Weight (kg) $73.0$ ( $63.0-80.0$ )Height (cm) $165$ ( $160-171$ )Body mass index $26.4$ ( $23.1-31.2$ )Race $Caucasian$ $658$ ( $87.7$ )East Asian $33$ ( $4.4$ )South Asian $17$ ( $2.3$ )African Canadian $12$ ( $1.6$ )First nation $10$ ( $1.3$ )Other $20$ ( $2.7$ )Medical history $U$ Diabetes mellitus on medication $16$ ( $2.1$ )Hypertension $241$ ( $32.1$ )Dyslipidaemia $152$ ( $20.3$ )Current smoker $87$ ( $11.6$ )Family history of premature CAD $285$ ( $38.0$ )No cardiac risk factors $21$ ( $9.5$ )History of previous revascularization $13$ ( $1.7$ )History of previous SCAD $42$ ( $5.6$ )History of Ne ard failure $3$ ( $0.4$ )Relevant clinical history $100$ ( $13.3$ )History of migraines $244$ ( $32.5$ )History of migraines $244$ ( $32.5$ )History of migraines $244$ ( $32.5$ )History of depression $146$ ( $19.5$ )On medication for depression $111$ ( $14.8$ )History of anxiety $148$ ( $19.7$ )On medication for anxiety $88$ ( $11.7$ )Thyroid dysfunction $97$ ( $12.9$ )  |  |                  |
|---|--|------------------|
| Sex (female)       664 (88.5)         Weight (kg)       73.0 (63.0-80.0)         Height (cm)       165 (160-171)         Body mass index       26.4 (23.1-31.2)         Race       Caucasian         Caucasian       658 (87.7)         East Asian       33 (4.4)         South Asian       17 (2.3)         African Canadian       12 (1.6)         First nation       10 (1.3)         Other       20 (2.7)         Medical history       J         Diabetes mellitus       34 (4.5)         Diabetes mellitus on medication       16 (2.1)         Hypertension       241 (32.1)         Dyslipidaemia       152 (20.3)         Current smoker       87 (11.6)         Family history of premature CAD       285 (38.0)         No cardiac risk factors       71 (9.5)         History of previous revascularization       13 (1.7)         History of previous MI       63 (8.4)         Confirmed cases of previous SCAD       42 (5.6)         History of cVA       26 (3.5)         History of heigraines       244 (32.5)         History of migraines       244 (32.5)         History of depression       146 (19.5)         On medicat   | Mean $\pm$ SD, median (Q1–Q3), or <i>n</i> (%) | N = 750          |
| Weight (kg)         73.0 (63.0-80.0)           Height (cm)         165 (160-171)           Body mass index         26.4 (23.1-31.2)           Race  | Age (years)                                    | 51.8 ± 10.2      |
| Height (cm)165 (160–171)Body mass index $26.4$ (23.1–31.2)Race $26.4$ (23.1–31.2)Caucasian $658$ (87.7)East Asian $33$ (4.4)South Asian $17$ (2.3)African Canadian $12$ (1.6)First nation $10$ (1.3)Other $20$ (2.7)Medical history $20$ (2.7)Diabetes mellitus on medication $16$ (2.1)Hypertension $241$ (32.1)Dyslipidaemia $152$ (20.3)Current smoker $87$ (11.6)Family history of premature CAD $285$ (38.0)No cardiac risk factors $254$ (33.9) $\geq 3$ cardiac risk factors $71$ (9.5)History of previous revascularization $13$ (1.7)History of previous SCAD $42$ (5.6)History of heart failure $3$ (0.4)Relevant clinical history $100$ (13.3)History of depression $146$ (19.5)On medication for depression $111$ (14.8)History of anxiety $88$ (11.7)On medication for anxiety $88$ (11.7)Thyroid dysfunction $97$ (12.9)  | Sex (female)                                   | 664 (88.5)       |
| Body mass index $26.4 (23.1-31.2)$ RaceCaucasian $658 (87.7)$ East Asian $33 (4.4)$ South Asian $17 (2.3)$ African Canadian $12 (1.6)$ First nation $10 (1.3)$ Other $20 (2.7)$ Medical history $16 (2.1)$ Diabetes mellitus on medication $16 (2.1)$ Hypertension $241 (32.1)$ Dyslipidaemia $152 (20.3)$ Current smoker $87 (11.6)$ Family history of premature CAD $285 (38.0)$ No cardiac risk factors $254 (33.9)$ $\geq 3$ cardiac risk factors $71 (9.5)$ History of previous revascularization $13 (1.7)$ History of previous SCAD $42 (5.6)$ History of heart failure $3 (0.4)$ Relevant clinical history $100 (13.3)$ History of depression $146 (19.5)$ On medication for depression $111 (14.8)$ History of anxiety $48 (11.7)$ On medication for anxiety $88 (11.7)$ Thyroid dysfunction $97 (12.9)$   | Weight (kg)                                    | 73.0 (63.0–80.0) |
| Race           Caucasian         658 (87.7)           East Asian         33 (4.4)           South Asian         17 (2.3)           African Canadian         12 (1.6)           First nation         10 (1.3)           Other         20 (2.7)           Medical history         20           Diabetes mellitus         34 (4.5)           Diabetes mellitus on medication         16 (2.1)           Hypertension         241 (32.1)           Dyslipidaemia         152 (20.3)           Current smoker         87 (11.6)           Family history of premature CAD         285 (38.0)           No cardiac risk factors         254 (33.9)           ≥3 cardiac risk factors         71 (9.5)           History of previous revascularization         13 (1.7)           History of previous MI         63 (8.4)           Confirmed cases of previous SCAD         42 (5.6)           History of CVA         26 (3.5)           History of heart failure         3 (0.4)           Relevant clinical history         100 (13.3)           History of migraines         244 (32.5)           History of depression         146 (19.5)           On medication for depression         111 (14.8) | Height (cm)                                    | 165 (160–171)    |
| Caucasian658 (87.7)East Asian33 (4.4)South Asian17 (2.3)African Canadian12 (1.6)First nation10 (1.3)Other20 (2.7)Medical history20 (2.7)Medical history16 (2.1)Diabetes mellitus on medication16 (2.1)Hypertension241 (32.1)Dyslipidaemia152 (20.3)Current smoker87 (11.6)Family history of premature CAD285 (38.0)No cardiac risk factors254 (33.9) $\geq$ 3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous SCAD42 (5.6)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of migraines244 (32.5)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety48 (11.7)Thyroid dysfunction97 (12.9)   | Body mass index                                | 26.4 (23.1–31.2) |
| East Asian33 (4.4)South Asian17 (2.3)African Canadian12 (1.6)First nation10 (1.3)Other20 (2.7)Medical history20 (2.7)Diabetes mellitus34 (4.5)Diabetes mellitus on medication16 (2.1)Hypertension241 (32.1)Dyslipidaemia152 (20.3)Current smoker87 (11.6)Family history of premature CAD285 (38.0)No cardiac risk factors254 (33.9) $\geq$ 3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous SCAD42 (5.6)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | Race   |                  |
| South Asian17 (2.3)African Canadian12 (1.6)First nation10 (1.3)Other20 (2.7)Medical history20 (2.7)Medical history34 (4.5)Diabetes mellitus on medication16 (2.1)Hypertension241 (32.1)Dyslipidaemia152 (20.3)Current smoker87 (11.6)Family history of premature CAD285 (38.0)No cardiac risk factors254 (33.9) $\geq$ 3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous SCAD42 (5.6)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | Caucasian                                      | 658 (87.7)       |
| African Canadian12 (1.6)First nation10 (1.3)Other20 (2.7)Medical history20 (2.7)Diabetes mellitus34 (4.5)Diabetes mellitus on medication16 (2.1)Hypertension241 (32.1)Dyslipidaemia152 (20.3)Current smoker87 (11.6)Family history of premature CAD285 (38.0)No cardiac risk factors254 (33.9) $\geq$ 3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous SCAD42 (5.6)History of cVA26 (3.5)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)  | East Asian                                     | 33 (4.4)         |
| First nation10 (1.3)Other20 (2.7)Medical historyJabetes mellitusDiabetes mellitus on medication16 (2.1)Hypertension241 (32.1)Dyslipidaemia152 (20.3)Current smoker87 (11.6)Family history of premature CAD285 (38.0)No cardiac risk factors254 (33.9)≥3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous SCAD42 (5.6)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)  | South Asian                                    | 17 (2.3)         |
| Other20 (2.7)Medical history34 (4.5)Diabetes mellitus34 (4.5)Diabetes mellitus on medication16 (2.1)Hypertension241 (32.1)Dyslipidaemia152 (20.3)Current smoker87 (11.6)Family history of premature CAD285 (38.0)No cardiac risk factors254 (33.9)≥3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous RII63 (8.4)Confirmed cases of previous SCAD42 (5.6)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)  | African Canadian                               | 12 (1.6)         |
| Medical historyDiabetes mellitus34 (4.5)Diabetes mellitus on medication16 (2.1)Hypertension241 (32.1)Dyslipidaemia152 (20.3)Current smoker87 (11.6)Family history of premature CAD285 (38.0)No cardiac risk factors254 (33.9)≥3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous SCAD42 (5.6)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)  | First nation                                   | 10 (1.3)         |
| Diabetes mellitus34 (4.5)Diabetes mellitus on medication16 (2.1)Hypertension241 (32.1)Dyslipidaemia152 (20.3)Current smoker87 (11.6)Family history of premature CAD285 (38.0)No cardiac risk factors254 (33.9)≥3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous MI63 (8.4)Confirmed cases of previous SCAD42 (5.6)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | Other  | 20 (2.7)         |
| Diabetes mellitus on medication16 (2.1)Hypertension241 (32.1)Dyslipidaemia152 (20.3)Current smoker87 (11.6)Family history of premature CAD285 (38.0)No cardiac risk factors254 (33.9) $\geq$ 3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous SCAD42 (5.6)History of CVA26 (3.5)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | Medical history                                |                  |
| Hypertension241 (32.1)Dyslipidaemia152 (20.3)Current smoker87 (11.6)Family history of premature CAD285 (38.0)No cardiac risk factors254 (33.9) $\geq$ 3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous MI63 (8.4)Confirmed cases of previous SCAD42 (5.6)History of CVA26 (3.5)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)  | Diabetes mellitus                              | 34 (4.5)         |
| Dyslipidaemia152 (20.3)Current smoker87 (11.6)Family history of premature CAD285 (38.0)No cardiac risk factors254 (33.9)≥3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous RI63 (8.4)Confirmed cases of previous SCAD42 (5.6)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety88 (11.7)Thyroid dysfunction97 (12.9)  | Diabetes mellitus on medication                | 16 (2.1)         |
| Current smoker87 (11.6)Family history of premature CAD285 (38.0)No cardiac risk factors254 (33.9)≥3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous MI63 (8.4)Confirmed cases of previous SCAD42 (5.6)History of CVA26 (3.5)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)  | Hypertension                                   | 241 (32.1)       |
| Family history of premature CAD $285$ (38.0)No cardiac risk factors $254$ (33.9) $\geq 3$ cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous MI63 (8.4)Confirmed cases of previous SCAD42 (5.6)History of CVA26 (3.5)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety88 (11.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | Dyslipidaemia                                  | 152 (20.3)       |
| No cardiac risk factors $254 (33.9)$ $\geq 3$ cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous MI63 (8.4)Confirmed cases of previous SCAD42 (5.6)History of CVA26 (3.5)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | Current smoker                                 | 87 (11.6)        |
| ≥3 cardiac risk factors71 (9.5)History of previous revascularization13 (1.7)History of previous MI63 (8.4)Confirmed cases of previous SCAD42 (5.6)History of CVA26 (3.5)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | Family history of premature CAD                | 285 (38.0)       |
| History of previous revascularization13 (1.7)History of previous MI63 (8.4)Confirmed cases of previous SCAD42 (5.6)History of CVA26 (3.5)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of migraines244 (32.5)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)  | No cardiac risk factors                        | 254 (33.9)       |
| History of previous MI63 (8.4)Confirmed cases of previous SCAD42 (5.6)History of CVA26 (3.5)History of heart failure3 (0.4)Relevant clinical history100 (13.3)History of migraines244 (32.5)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | ≥3 cardiac risk factors                        | 71 (9.5)         |
| Confirmed cases of previous SCAD42 (5.6)History of CVA26 (3.5)History of heart failure3 (0.4)Relevant clinical historyTinnitusTinnitus100 (13.3)History of migraines244 (32.5)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | History of previous revascularization          | 13 (1.7)         |
| History of CVA26 (3.5)History of heart failure3 (0.4)Relevant clinical history100 (13.3)Tinnitus100 (13.3)History of migraines244 (32.5)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | History of previous MI                         | 63 (8.4)         |
| History of heart failure3 (0.4)Relevant clinical history100 (13.3)Tinnitus100 (13.3)History of migraines244 (32.5)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | Confirmed cases of previous SCAD               | 42 (5.6)         |
| Relevant clinical historyTinnitus100 (13.3)History of migraines244 (32.5)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)  | History of CVA                                 | 26 (3.5)         |
| Tinnitus100 (13.3)History of migraines244 (32.5)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | ,  | 3 (0.4)          |
| History of migraines244 (32.5)History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | Relevant clinical history                      |                  |
| History of depression146 (19.5)On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)   | Tinnitus                                       | 100 (13.3)       |
| On medication for depression111 (14.8)History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)  | History of migraines                           | 244 (32.5)       |
| History of anxiety148 (19.7)On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)  | History of depression                          | 146 (19.5)       |
| On medication for anxiety88 (11.7)Thyroid dysfunction97 (12.9)  | On medication for depression                   | 111 (14.8)       |
| Thyroid dysfunction97 (12.9)  | , ,  | 148 (19.7)       |
| ,   | On medication for anxiety                      | 88 (11.7)        |
| Hypothyroid 85 (11 3)   | Thyroid dysfunction                            | 97 (12.9)        |
| (11.5)  | Hypothyroid                                    | 85 (11.3)        |

CAD, coronary artery dissection; CVA, cerebrovascular accident; SD, standard deviation.

defibrillator). Troponin levels were elevated in 97.6%. The main presenting symptom was chest pain (91.5%). Median LVEF was 55% (50– 60); 25.6% had LVEF <50% and 3.8% had LVEF <35%. Wall motion abnormality occurred in 82.3%.

Angiographic characteristics are described in *Table 3*. Optical coherence tomography was performed in 5.5% and IVUS in 2.1%. Majority of SCAD involved a single coronary artery territory (86.9%). The most common coronary artery dissected was the left anterior descending artery and branches (52.1%) (*Figure 3*). Among the 1002 dissected arteries, majority had Type 2 angiographic SCAD (60.2%). Type 1 SCAD occurred in 29.0% and Type 3 SCAD in 10.8%. Median angiographic stenosis was 79.0% (65.0–100), and median dissection length was 33.2 mm (22.2–48.9).




Figure 2 Histogram of age distribution.

Precipitating stressors and predisposing conditions were frequently observed (Table 4). Overall, 66.4% reported potential precipitating stressors: emotional stressors 50.3% (perceived stress scale >20 in 41.2%), physical stressors 28.9%, and heavy isometric activities lifting >50 pounds in 9.8%. Potential predisposing conditions occurred in 49.9%, but 45.2% had no or incomplete screening for FMD (Supplementary material online, Table SB). Fibromuscular dysplasia was most commonly observed, with multifocal changes in 31.1% of our overall cohort [56.7% (233/411) amongst those who had complete FMD screening]. Of the FMD screens performed, 52.4% were CT angiography, 43.6% catheter-based angiography, and 4.0% MR angiography. Cerebral aneurysm was present in 7.1% who underwent cerebrovascular imaging. Other predisposing conditions were less frequent, and 50.1% were deemed idiopathic. Relevant family history included any aneurysm in 13.5%, sudden death 15.1%, any arterial dissection 3.1%, SCAD 2.4%, and FMD 0.8%.

Majority of patients (n = 648, 86.4%) were treated conservatively as the first initial strategy; of these, 13 (2.0%) required subsequent inhospital PCI, and 2 (0.3%) underwent CABG. Overall, 110 patients (14.7%) underwent revascularization (14.1% PCI, 0.7% CABG) (*Table 5* and *Take home figure*). Eleven (1.5%) underwent fibrinolysis, of which four required subsequent PCI. Of the 106 patients who underwent PCI, 85 cases were planned, 18 unplanned, and three were performed on non-SCAD lesions (SCAD was missed). The rationale for revascularization are listed in Supplementary material online, *Table SC*, with the most common reasons being ongoing chest pain or ECG ischaemia. Of the 103 PCI cases performed for SCAD, 29.1% was deemed successful, 40.8% partially successful, and 30.1% unsuccessful.

The median hospital stay was 4 days (IQR 3 days). During hospitalization, MAE occurred in 66 (8.8%) (*Table 6*). latrogenic catheterinduced dissection occurred in 9 cases (1.2%). High-risk presentation occurred in 7.6%. Peripartum SCAD patients were more likely to have high-risk presentation (23.5% vs. 6.8%, P = 0.003) than nonperipartum patients, as well as higher in-hospital MAE, higher troponin elevation, more multivessel SCAD, and iatrogenic dissections (Supplementary material online, *Table SD*). Post-discharge within

#### Table 2 Hospital presenting characteristics

| Median (Q1-Q3) or <i>n</i> (%)          | N = 750        |
|---|----------------|
| Acute coronary syndrome                 |                |
| STEMI                                   | 223 (29.7)     |
| NSTEMI                                  | 524 (69.9)     |
| Unstable angina                         | 3 (0.4)        |
| Presenting main symptom                 | 5 (0.7)        |
| Chest discomfort                        | 686 (91.5)     |
| Back discomfort                         | 15 (2.0)       |
| Shoulder or arm discomfort              | 10 (1.3)       |
| Dyspnoea                                | 7 (0.9)        |
| Arrhythmia                              | 8 (1.1)        |
| Other                                   | 24 (3.2)       |
| Troponin levels                         | 21 (3.2)       |
| Elevated troponin                       | 732 (97.6)     |
| Troponin not elevated                   | 4 (0.5)        |
| Troponin value not available            | 14 (1.9)       |
| ECG changes                             | 11(1.7)        |
| Normal ECG                              | 170 (22.7)     |
| Non-specific changes                    | 81 (10.8)      |
| T inversion                             | 138 (18.4)     |
| ST depression                           | 47 (6.3)       |
| ST elevation <1 mm                      | 85 (11.3)      |
| ST elevation >1 mm                      | 187 (24.9)     |
| Q waves                                 | 11 (1.5)       |
| LBBB                                    | 5 (0.7)        |
| Other                                   | 26 (3.5)       |
| Ventricular tachycardia or fibrillation | 61 (8.1)       |
| Left ventricular function assessment    |                |
| Ejection fraction assessed              | 737 (98.2)     |
| Angiogram                               | 491 (65.5)     |
| Echocardiogram                          | 243 (32.4)     |
| Initial ejection fraction (%)           | 55 (50-60)     |
| Ejection fraction <50%                  | 188/734 (25.6) |
| Ejection fraction <35%                  | 28/734 (3.8)   |
| Wall motion abnormality                 | . ,            |
| No abnormality                          | 114 (15.2)     |
| Hypokinesis                             | 359 (47.9)     |
| Akinesis                                | 215 (28.7)     |
| Dyskinesis                              | 43 (5.7)       |
| Not assessed                            | 19 (2.5)       |

ECG, electrocardiogram; LBBB, left bundle branch block; NSTEMI, non-ST elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.

30 days, the composite MACE was 2.7%. The overall MACE within 30 days was 8.8% (*Take home figure*). Other complications within 30 days included re-admission for chest pain in 2.5% and emergency room visit for cardiac reasons 4.9%.


Medications at hospital discharge and last clinical follow-up are listed in Supplementary material online, *Table SE*. The vast majority of patients were discharged home on aspirin (93.7%), 67.4% on ADP antagonist, and 84.8% on beta-blocker.


# Table 3 Spontaneous coronary artery dissection angiographic characteristics

| N (%), median (Q1–Q3)         N = 750           Radial approach catheterization         556 (74.1)           5         122 (25.1) |
|---|
|   |
|   |
| Femoral approach catheterization 192 (25.6)   |
| OCT-confirmed SCAD 41 (5.5)   |
| IVUS-confirmed SCAD 16 (2.1)  |
| Number of non-contiguous SCAD arteries  |
| 1 652 (86.9)  |
| 2 88 (11.7)   |
| 3 10 (1.3)  |
| Number of affected SCAD segments  |
| 1 561 (74.8)  |
| 2 147 (19.6)  |
| 3 24 (3.2)  |
| 4 16 (2.1)  |
| 5 1 (0.1)   |
| 6 1 (0.1)   |
| ≥2 segments 189 (25.2)  |
| Dissected coronary arteries   |
| LM 11 (1.5)   |
| LAD 391 (52.1)  |
| LCX 283 (37.7)  |
| RCA 174 (23.2)  |
| LM or prox LCX or prox LAD 57 (7.6)   |
| Angiographic SCAD type N = 1002 dissections   |
| 1 291 (29.0)  |
| 2 603 (60.2)  |
| 2A 343 (34.2)   |
| 2B 260 (25.9)   |
| 3 108 (10.8)  |
| Worse TIMI flow   |
| 0 89 (8.9)  |
| 1 185 (18.5)  |
| 2 89 (8.9)  |
| 3 639 (63.8)  |
| QCA characteristics   |
| Total occlusion (stenosis 100%) 307 (30.6)  |
| Vessel diameter (mm) 2.4 (2.0–3.0)  |
| Segment diameter stenosis (%) 79.0 (65.0–100)   |
| Segment length (mm) 33.2 (22.2–48.9)  |

LAD, left anterior descending; LCX, left circumflex artery; QCA, quantitative coronary analysis; RCA, right coronary artery; TIMI: thrombolysis in myocardial infarction.

Univariates associated with in-hospital MAE included age, smoking history,  $\geq$ 5 pregnancies, and peripartum SCAD (Supplementary material online, *Table SF, Figure 4*). In multivariable analysis, only peripartum SCAD remained significantly associated with in-hospital MAE. Peripartum SCAD was also independent predictor of high-risk presentation (OR 4.56, 95% CI 1.94–10.62; *P* < 0.001). Univariates associated with 30-day MACE included age, smoking history, CTDs,  $\geq$ 5 pregnancies, and peripartum SCAD. However, in multivariable





analysis, only CTDs and peripartum SCAD remain significantly associated with 30-day MACE.

## Discussion

This is the first prospective multicentre study of patients presenting acutely with non-atherosclerotic SCAD. It is also the largest and the only study with core laboratory adjudicated SCAD to date. We found that survival to 30 days was good despite the majority being treated conservatively, but 30-day MACE was high (8.8%). Important novel findings include peripartum SCAD and CTD being independent predictors of 30-day MACE.

Our study differs from prior SCAD case series, and extends beyond the single-centre Vancouver experience that we previously reported.<sup>10,11,16</sup> Enrolling patients prospectively after acute SCAD ensures that all CV outcomes were methodically collected to ascertain the natural history of this disease. Clinical events were reviewed and verified by source documentations to ensure accuracy. This article provides detailed short-term outcomes in SCAD patients, which were not previously reported and are important to guide management and physician/patient education. Survival to discharge was excellent, with only one in-hospital death, and the remainder survived to 30 days. Despite the majority (86.4%) being treated conservatively as the initial treatment strategy, most patients survived hospitalization without MAE. Of note, in-hospital recurrent MI occurred in 4.0% and unplanned revascularization in 2.5%, highlighting the need for monitoring in-hospital for recurrent ischaemia and potential urgent revascularization for failed conservative therapy. Importantly, high-risk presentations were not infrequent (7.6%). Conservative therapy may be inadequate for these patients, and clinicians should have low thresholds for revascularization and/or supportive haemodynamic therapies.

Within 30 days after discharge, recurrent MI occurred in a further 2.1% of patients, and unplanned revascularization in 0.1%. This highlights the small but residual risks of extension or recurrent

# Table 4Precipitating stressors and potential predisposing conditions

| N (%)                                   | N = 750    |  |
|---|------------|--|
| Precipitating stressors                 |            |  |
| Emotional stress (rated high or severe) | 377 (50.3) |  |
| Perceived stress scale $\geq 20$        | 288 (41.2) |  |
| Unusually intense physical stress       | 216 (28.9) |  |
| Isometric stress >50 lb                 | 74 (9.8)   |  |
| Cocaine/amphetamine use                 | 2 (0.3)    |  |
| Valsalva-type stress                    | 90 (12.0)  |  |
| No precipitating factor                 | 252 (33.6) |  |
| Predisposing conditions                 |            |  |
| Fibromuscular dysplasia                 | 233 (31.1) |  |
| Systemic inflammatory disease           | 35 (4.7)   |  |
| Connective tissue disorder              | 27 (3.6)   |  |
| Active hormonal therapy                 | 75 (10.0)  |  |
| Peripartum                              | 34 (4.5)   |  |
| Grand multigravida (≥5 pregnancies)     | 67 (8.9)   |  |
| Multiparous (≥4 births)                 | 64 (8.5)   |  |
| Grand multiparity (≥5 births)           | 17 (2.3)   |  |
| Idiopathic (none of the above)          | 376 (50.1) |  |

dissections post-SCAD, and the need for surveillance of recurrent ischaemia post-discharge. Importantly, repeat presentations with chest pains or other cardiac reasons were frequent (4.9%) within 30 days of SCAD. Although half of emergency room visits did not require admission, these patients should be investigated for recurrent MI. Interestingly, stroke/TIA occurred in 1.2% within 30 days; most were deemed ischaemic, except for one cerebral haemorrhage (no carotid/vertebral dissection). Peripartum SCAD and CTD were independent predictors of 30-day MACE, highlighting the need for clinical vigilance in these cohorts.

| Table 5         Management strategy and outcomes |              |  |
|--|--------------|--|
| N (%)  | N = 750      |  |
| Treatment strategy                               |              |  |
| Conservative                                     | 632 (84.3)   |  |
| Fibrinolysis                                     | 11 (1.5)     |  |
| Revascularization (PCI or CABG)                  | 110 (14.7)   |  |
| PCI  | 106 (14.1)   |  |
| CABG   | 5 (0.7)      |  |
| PCI performed during admission                   | N = 106      |  |
| Planned or ad hoc                                | 85 (80.2)    |  |
| Unplanned  | 18 (17.0)    |  |
| To non-SCAD segment (missed SCAD)                | 3 (2.8)      |  |
| SCAD PCI procedures and outcomes                 | N=103        |  |
| Wiring only                                      | 15 (14.6)    |  |
| Balloon angioplasty                              | 21 (20.4)    |  |
| Cutting balloon                                  | 5 (4.9)      |  |
| Stent placement                                  | 67 (65.0)    |  |
| Number of stents implanted                       |              |  |
| 1  | 21/67 (31.4) |  |
| 2  | 23/67 (34.1) |  |
| 3  | 15/67 (22.4) |  |
| 4 or more  | 8/67 (11.9)  |  |
| Final TMI flow                                   |              |  |
| 0  | 16 (15.7)    |  |
| 1  | 6 (5.9)      |  |
| 2  | 13 (12.7)    |  |
| 3  | 67 (65.7)    |  |
| PCI effect on TIMI flow                          |              |  |
| Improved   | 59 (57.6)    |  |
| Unchanged  | 40 (38.8)    |  |
| Worse  | 4 (3.9)      |  |
| Propagation of SCAD during PCI                   | 33 (32.0)    |  |
| Overall PCI success                              |              |  |
| Successful                                       | 30 (29.1)    |  |
| Partial success                                  | 42 (40.8)    |  |
| Unsuccessful                                     | 31 (30.1)    |  |

Our study also provides valuable insights on the background characteristics of SCAD patients. The mean age of our 'all-comers' cohort was 51.8 years, reflecting a young to middle-aged group of women at risk for this condition.<sup>16–19</sup> A few smaller studies reported younger mean ages in the forties,<sup>20–22</sup> which were likely inaccurate as these were small, retrospective studies, and preferentially included patients who had more severe SCAD (younger peripartum cases) or selfselected (voluntary online registry). The age range of patients in our study was 24–89 years (9.2% were older than 65 years), and 88.5% were women, therefore, SCAD should be in the differential diagnosis of all women presenting with MI, not just young women.

Precipitating stressors were commonly reported (66.4%) in our SCAD cohort, including emotional and/or physical stress. This important observation should be taken into consideration for subsequent lifestyle changes, including referral to cardiac rehabilitation


| le 6 | In-hospital and 30-day cardiovascular events |
|------|--|
| )    | N = 750                                      |

Tabl

| n (%)                              | N = 750                    |  |
|------------------------------------|----------------------------|--|
| Overall in-hospital MAE            | 66 (8.8) (95% CI 6.9–11.1) |  |
| Death                              | 1 (0.1)                    |  |
| Recurrent MI                       | 30 (4.0)                   |  |
| Extension of SCAD segment          | 15 (50.0)                  |  |
| latrogenic dissection              | 9 (30.0)                   |  |
| Other                              | 6 (20.0)                   |  |
| Severe ventricular arrhythmia      | 29 (3.9)                   |  |
| Requiring ICD                      | 6 (0.8)                    |  |
| Haemodynamic instability           | 15 (2.0)                   |  |
| Use of inotropes                   | 9 (1.2)                    |  |
| IABP                               | 6 (0.8)                    |  |
| LVAD                               | 2 (0.3)                    |  |
| ECMO                               | 2 (0.3)                    |  |
| LV rupture requiring surgery       | 1 (0.1)                    |  |
| Heart transplant                   | 0 (0)                      |  |
| Unplanned revascularization        | 19 (2.5)                   |  |
| Stroke/TIA                         | 6 (0.8)                    |  |
| Congestive heart failure           | 2 (0.3)                    |  |
| Post-discharge 30-day MACE         | 19 (2.5) (95% Cl 1.5–3.9)  |  |
| Death                              | 0 (0)                      |  |
| Recurrent MI                       | 16 (2.1)                   |  |
| Extension of SCAD segment          | 8 (50.0)                   |  |
| latrogenic dissection              | 1 (6.3)                    |  |
| New de novo SCAD                   | 1 (6.3)                    |  |
| Other                              | 6 (37.5)                   |  |
| Unplanned revascularization        | 1 (0.1)                    |  |
| Stroke/TIA                         | 3 (0.4)                    |  |
| Congestive heart failure           | 1 (0.1)                    |  |
| Total 30-day MACE                  | 66 (8.8) (95% Cl 6.9–11.1) |  |
| Death                              | 1 (0.1)                    |  |
| Recurrent MI                       | 46 (6.1)                   |  |
| Unplanned revascularization        | 20 (2.7)                   |  |
| Stroke/TIA                         | 9 (1.2)                    |  |
| Congestive heart failure           | 3 (0.4)                    |  |
| Other complications within 30 days |                            |  |
| Pericarditis                       | 14 (1.9)                   |  |
| New atrial fibrillation            | 7 (0.9)                    |  |
| Cardiac emergency room visit       | 37 (4.9)                   |  |
| Admission for chest pain           | 19 (2.5)                   |  |

ECMO, extracorporeal membrane oxygenation; LV, left ventricle; LVAD, left ventricular assist device.

programmes with SCAD-specific recommendations that include restrictions in weight lifting and psychosocial support.<sup>23</sup> Predisposing conditions were also common (half our patients), even though only 54.8% had complete FMD screen. We recommended that FMD screening be performed for all patients; however, this was at the discretion of treating physicians and were not routinely done. As such, only 31.1% of the overall cohort screened positive for FMD (56.7% amongst those who had complete FMD screening), which was lower than our previously




Take home figure Top: treatment flow diagram and bottom: cumulative incidence of 30-day major adverse cardiovascular events.

reported co-prevalence of 63-86%.<sup>10,11,16</sup> Furthermore, CTA was the primary mode of FMD screen (lower sensitivity) in this study, as opposed to catheter-angiography in our prior Vancouver series.<sup>10,11</sup> We expect more patients to be screened for FMD during remainder of the study, and the incidence of extracoronary FMD should be higher. Other potential predisposing conditions were much less frequent. Patients with peripartum SCAD had higher likelihood of high-risk presentation and inhospital MAE. They had more LM and proximal artery SCAD, multivessel, and multisegmental SCAD, which culminated in larger MI and worse LVEF. These findings confirm prior Mayo Clinic study on pregnancy-associated SCAD, although they included patients who were pregnant or  $\leq 12$  weeks postpartum,<sup>24</sup> whereas we defined peripartum as the period from 3rd trimester pregnancy to within 12 months of delivery.

Coronary angiographic core laboratory analysis was central for patient inclusion for our study, and a fundamental strength of this study. This ensured that all enrolled patients had verified angiographic SCAD and were uniformly classified.<sup>5,6</sup> Angiographic diagnosis of SCAD can be challenging, both with under-diagnosis and 'over-calling'. We have observed that angiographers have improved their SCAD diagnostic skills on angiography remarkably over the past few years. Some critics are concerned that the pendulum may have swung too much the other way with 'over-calling'. Twenty-four cases were excluded by our core laboratory. In ambiguous cases, intracoronary imaging can be invaluable to confirm diagnosis. Of note, iatrogenic catheter-induced dissection can be a drastic complication in patients with SCAD,<sup>25</sup> and our reported incidence was 1.3%. Thus, meticulous and cautious angiographic techniques are mandatory when imaging SCAD patients.

From early experience, we learnt that PCI for SCAD patients was fraught with challenges, including poor success rates, extension of dissections, iatrogenic dissections, and need for long stents.<sup>10</sup> The decision to revascularize can differ widely amongst clinicians and this





**Figure 4** Forest plot for multivariable predictors of in-hospital major adverse events and 30-day major adverse cardiovascular events. <sup>a</sup>Adjusted model includes peripartum, connective tissue disease, and number of pregnancies. <sup>b</sup>Adjusted model includes peripartum, connective tissue disease, and history of smoking.

is the first study to capture the rationale for revascularization. In our cohort, 86.4% of patients were treated conservatively and the in-hospital event rates were highly favourable. For those that underwent revascularization, the majority had PCI, with 30.1% being unsuccessful. These findings reaffirm current recommendations for conservative therapy as first-line treatment in position statements.<sup>2,7</sup> However, patients with high-risk presentation (e.g. peripartum SCAD) should be considered for emergent invasive management if conservative therapy is unlikely to be sufficient.

### Limitations

Our study is non-randomized, however, our large, multicentre, prospective enrolment of SCAD patients enabled us to evaluate the natural history and outcomes according to real-world management in an objective manner. We attempted enrolling all consecutive nonatherosclerotic SCAD patients at each site to minimize bias; however, we cannot be certain that all patients were enrolled, particularly those who did not survive to hospital presentation, or diagnosis that was missed on angiography. A small proportion (17.6%, n = 132) of this current cohort was included in prior publication as part of the Vancouver SCAD cohort<sup>16</sup>; the remainder majority in this current study were new unreported patients. The majority (60.0%) were enrolled acutely in-hospital, 31.3% within a month, and the remainder within 3 months of SCAD presentation. However, we only allowed post-discharge enrolment of patients if all in-hospital and readmission records can be obtained to ensure that all events were collected. The small number of peripartum patients rendered it challenging to make definitive conclusions; nevertheless, peripartum SCAD remained an independent predictor of high-risk presentation and 30-day MACE.

## Conclusion

Spontaneous coronary artery dissection predominantly affects young and middle-aged women, and primarily presents with MI. Despite conservative therapy in the majority of patients, acute in-hospital and 30-day survival is good. However, significant CV complications accrued within the first 30 days post-SCAD, including recurrent MI, unplanned revascularization, stroke, and recurrent emergency room visits. Longer-term follow-up of this large prospective cohort, and further investigations on pathophysiology, risk and predictors of recurrence, and management are warranted.

## Supplementary material

Supplementary material is available at European Heart Journal online.

### Acknowledgements

The authors would like to thank the University of British Columbia Cardiology Research group (Jackie Chow, Andrew Starovoytov, Naomi Uchida, Robyn Tkatch, Brady Robinson, and Ngaire Meadows) for co-ordinating the study, the Cardiovascular Imaging Research team (G.B.J.M., Eunice Yeoh, Craig Kamimura, and Arnold Ryomoto) for angiographic analyses, the BC Center for Improved Cardiovascular Health (K.H., Defen Peng, Yinshan Zhao, and Melissa Pak) for statistical analyses, and the site principal investigators and team for participation and patient enrolment [Vancouver General Hospital (J.S.), Hamilton General Hospital (T.S.), University of Ottawa Heart Institute (D.S.), St. Boniface Hospital (K.M.), Royal Alexandra Hospital (N.B.), Prairie Vascular Research Network (A.L.), Queen Elizabeth Health Centre (H.B.), London Health Sciences Centre (S.L.), Royal University Hospital (C.P.), St Mary's General Hospital (S.R.), Sunnybrook Health Sciences Centre (M.M.), University of Alberta (R.W.), St. John Regional Hospital (S.L.), Rouge Valley Health System (R.V.), St Paul's Hospital (E.A.), Foothills Hospital (B.H.), Montreal Heart Institute (R.I.), Cleveland Clinic Foundation (H.G.), University of Michigan (S.G.), St. Michael's Hospital (C.B.), Centre hospitalier de l'Université de Montréal (A.M.), and McGill University Health Centre (G.M.)].

### Funding

This work was supported by Canadian Institutes of Health Research, Abbott Vascular, AstraZeneca, St Jude Medical, and Servier.

Conflict of interest: J.S. has received unrestricted research grant supports (from the Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, National Institutes of Health, University of British Columbia Division of Cardiology, AstraZeneca, Abbott Vascular, St Jude Medical, Boston Scientific, and Servier), speaker honoraria (AstraZeneca, St Jude Medical, Boston Scientific, and Sunovion), consultancy and advisory board (AstraZeneca, St Jude Medical, Abbott Vascular, and SCAD Alliance), and proctorship honoraria (St Jude Medical and Boston Scientific). D.S. has received unrestricted research grant supports (from the Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, National Institutes of Health, Eli-Lilly, Spartan Biosciences, Roche Diagnostics, and Aggredyne), speaker honoraria and advisory board honoraria (AstraZeneca and Bayer). H.L.G. has received research support (from CVR Global), equity/intellectual property (Flexlife Health), and is on advisory board (FMD Society of America). A.L. reports speaking honoraria (Boehringer Ingelheim, Pfizer, BMS Sanofi, Novartis, Servier, and Bayer). S.G. has received research grants from the National Heart, Lung and Blood Institute (HL139672), NIH, Doris Duke Charitable Foundation, and the Frankel Cardiovascular Center at the University of Michigan. She is on advisory boards (FMD Society of America and SCAD Alliance). And all other authors have no conflict of interest.

### References

- Saw J, Mancini GB, Humphries KH. Contemporary review on spontaneous coronary artery dissection. J Am Coll Cardial 2016;68:297–312.
- 2. Hayes SN, Kim ESH, Saw J, Adlam D, Arslanian-Engoren C, Economy KE, Ganesh SK, Gulati R, Lindsay ME, Mieres JH, Naderi S, Shah S, Thaler DE, Tweet MS, Wood MJ; American Heart Association Council on Peripheral Vascular Disease; Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Genomic and Precision Medicine; and Stroke Council. Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. *Circulation* 2018;**137**:e523–e557.
- Mahmoud AN, Taduru SS, Mentias A, Mahtta D, Barakat AF, Saad M, Elgendy AY, Mojadidi MK, Omer M, Abuzaid A, Agarwal N, Elgendy IY, Anderson RD, Saw J. Trends of incidence, clinical presentation and in-hospital mortality among women with acute myocardial infarction with or without spontaneous coronary artery dissection: a population-based analysis. *JACC Cardiovasc Interv* 2018;**11**: 80–90.
- Saw J, Aymong E, Mancini J, Sedlak T, Starovoytov A, Ricci D. Nonatherosclerotic coronary artery disease in young women. *Can J Cardiol* 2014;**30**: 814–819.
- Saw J, Mancini GB, Humphries K, Fung A, Boone R, Starovoytov A, Aymong E. Angiographic appearance of spontaneous coronary artery dissection with intramural hematoma proven on intracoronary imaging. *Catheter Cardiovasc Interv* 2016;87:E54–E61.
- Saw J. Coronary angiogram classification of spontaneous coronary artery dissection. Catheter Cardiovasc Interv 2014;84:1115–1122.
- Adlam D, Alfonso F, Maas A, Vrints C; Writing Committee. European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. *Eur Heart J* 2018;39: 3353–3368.
- Alderman EL, Stadius M. The angiographic definitions of the bypass angioplasty revascularization investigation. *Coron Artery Dis* 1992;3:1189–1207.
- Vijayaraghavan R, Verma S, Gupta N, Saw J. Pregnancy-related spontaneous coronary artery dissection. *Circulation* 2014;**130**:1915–1920.
- Saw J, Aymong E, Sedlak T, Buller CE, Starovoytov A, Ricci D, Robinson S, Vuurmans T, Gao M, Humphries K, Mancini GB. Spontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. *Circ Cardiovasc Interv* 2014;**7**:645–655.
- Saw J, Ricci D, Starovoytov A, Fox R, Buller CE. Spontaneous coronary artery dissection: prevalence of predisposing conditions including fibromuscular dysplasia in a tertiary center cohort. JACC Cardiovasc Interv 2013;6:44–52.
- 12. Olin JW, Gornik HL, Bacharach JM, Biller J, Fine LJ, Gray BH, Gray WA, Gupta R, Hamburg NM, Katzen BT, Lookstein RA, Lumsden AB, Newburger JW, Rundek T, Sperati CJ, Stanley JC; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Radiology and Intervention; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Functional Genomics and Translational Biology; American Heart Association Council on the Kidney in Cardiovascular Disease; American Heart Association Council on the Kidney in Cardiovascular Disease; American Heart Association Stroke Council. Fibromuscular dysplasia: state of the science and critical unanswered

questions: a scientific statement from the American heart association. *Circulation* 2014;**129**:1048–1078.

- Koul AK, Hollander G, Moskovits N, Frankel R, Herrera L, Shani J. Coronary artery dissection during pregnancy and the postpartum period: two case reports and review of literature. *Catheter Cardiovasc Interv* 2001;**52**:88–94.
- 14. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Gabriel Steg P, Wijns W, Bassand J-P, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon J-L, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. *Eur Heart J* 2012;33:2551–2567.
- Main A, Prakash R, Starovoytov A, Sabbaghan A, Aymong E, Mancini GBJ, Saw J. Characteristics of extension and de novo recurrent spontaneous coronary artery dissection. *EuroIntervention* 2017;**13**:e1454–e1459.
- Saw J, Humphries K, Aymong E, Sedlak T, Prakash R, Starovoytov A, Mancini GBJ. Spontaneous coronary artery dissection: clinical outcomes and risk of recurrence. J Am Coll Cardiol 2017;70:1148–1158.
- Alfonso F, Paulo M, Lennie V, Dutary J, Bernardo E, Jiménez-Quevedo P, Gonzalo N, Escaned J, Bañuelos C, Pérez-Vizcayno MJ, Hernández R, Macaya C. Spontaneous coronary artery dissection: long-term follow-up of a large series of patients prospectively managed with a "conservative" therapeutic strategy. JACC Cardiovasc Interv 2012;5:1062–1070.
- Lettieri C, Zavalloni D, Rossini R, Morici N, Ettori F, Leonzi O, Latib A, Ferlini M, Trabattoni D, Colombo P, Galli M, Tarantini G, Napodano M, Piccaluga E, Passamonti E, Sganzerla P, Ielasi A, Coccato M, Martinoni A, Musumeci G, Zanini R, Castiglioni B. Management and long-term prognosis of spontaneous coronary artery dissection. *Am J Cardiol* 2015;**116**:66–73.
- Rogowski S, Maeder MT, Weilenmann D, Haager PK, Ammann P, Rohner F, Joerg L, Rickli H. Spontaneous coronary artery dissection: angiographic follow-up and long-term clinical outcome in a predominantly medically treated population. *Catheter Cardiovasc Interv* 2017;89:59–68.
- Tweet MS, Eleid MF, Best PJ, Lennon RJ, Lerman A, Rihal CS, Holmes DR Jr, Hayes SN, Gulati R. Spontaneous coronary artery dissection: revascularization versus conservative therapy. *Circ Cardiovasc Interv* 2014;7:777–786.
- Roura G, Ariza-Solé A, Rodriguez-Caballero IF, Gomez-Lara J, Ferreiro JL, Romaguera R, Teruel L, de Albert M, Gomez-Hospital JA, Cequier A. Noninvasive follow-up of patients with spontaneous coronary artery dissection with CT angiography. JACC Cardiovasc Imaging 2016;9:896–897.
- Tweet MS, Hayes SN, Pitta SR, Simari RD, Lerman A, Lennon RJ, Gersh BJ, Khambatta S, Best PJ, Rihal CS, Gulati R. Clinical features, management and prognosis of spontaneous coronary artery dissection. *Circulation* 2012;**126**: 579–588.
- Chou AY, Prakash R, Rajala J, Birnie T, Isserow S, Taylor CM, Ignaszewski A, Chan S, Starovoytov A, Saw J. The first dedicated cardiac rehabilitation program for patients with spontaneous coronary artery dissection: description and initial results. *Can J Cardiol* 2016;**32**:554–560.
- Tweet MS, Hayes SN, Codsi E, Gulati R, Rose CH, Best PJM. Spontaneous coronary artery dissection associated with pregnancy. J Am Coll Cardiol 2017;70: 426–435.
- Prakash R, Starovoytov A, Heydari M, Mancini GB, Saw J. Catheter-induced iatrogenic coronary artery dissection in patients with spontaneous coronary artery dissection. JACC Cardiovasc Interv 2016;9:1851–1853.